Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions

William Hinshaw, Chief Executive Officer of Fore, commented, “Plixorafenib is emerging as a potential first-in-class and best-in-class next-generation BRAF inhibitor with a simple, once daily, oral dosing regimen without the PK booster cobicistat. At Fore Bio, we initiated studies in three areas of very high unmet need where we believe plixorafenib’s unique mechanism has the potential to add important clinical innovation and benefit for patients while getting to market as rapidly as possible, including in BRAF V600E central nervous system (CNS) tumors, BRAF fusions and rare BRAF V600E solid tumors. Plixorafenib has demonstrated activity across a wide number of tumors with BRAF alterations and has now passed two rigorous interim analyses, one for BRAF V600E CNS tumors and one for tumors with BRAF fusions, both encouraging milestones for the FORTE program. As we look ahead to the remainder of 2026 and into next year, we expect to achieve several important milestones, including reporting topline results from the BRAF V600E CNS basket around the end of 2026, submitting an NDA for the treatment of BRAF V600E CNS tumors during the first half of 2027, and reporting topline results from the BRAF fusion basket during the second half of 2027.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib